Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | CTRC | Q99895 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16502467 | 0.86 | KDM4E (0.51) | PLAUABL1BCRMEN1NPC1 | |
| SCHEMBL16502520 | 0.85 | NAPRT (0.53) | SLC22A12PLA2G2DMAP4K4MCL1ACMSD | |
| SCHEMBL16502679 | 0.85 | PLA2G2D (0.47) | SLC22A12PLA2G2DMCL1ACMSDPLAU | |
| SCHEMBL16502471 | 0.84 | PLA2G2D (0.47) | SLC22A12PLA2G2DMAP4K4MCL1ACMSD | |
| SCHEMBL16502572 | 0.83 | MKNK1 (0.49) | SLC22A12PLA2G2DMAP4K4HDAC6NPC1 | |
| SCHEMBL7921958 | 0.83 | HTR5A (0.49) | — | |
| SCHEMBL16502589 | 0.83 | PLAU (0.45) | PLA2G2DMCL1ACMSDPLAUPTPN1 | |
| SCHEMBL1528162 | 0.81 | PLA2G2D (0.54) | SLC22A12PLA2G2DMCL1ACMSDPTPN1 | |
| SCHEMBL16502470 | 0.81 | KMO (0.61) | SLC22A12PLA2G2DABL1BCRRAB9A | |
| SCHEMBL8755930 | 0.79 | PLA2G2D (0.53) | SLC22A12PLA2G2DMCL1ACMSDPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| WO-2010090304-A1 | ACYLGUANIDINE DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | HTR5A, HTR2A, HTR1A | SLC22A12 1344/4885PLA2G2D 841/4885MAP4K4 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.